JUPITER NEUROSCIENCES, INC. 8-K

What Happened
Jupiter Neurosciences announced that on June 26, 2026 it appointed Tomas J. Philipson, Ph.D. (age 64) to its Board of Directors, effective immediately. Dr. Philipson will serve until the next annual meeting of stockholders and was also named to the Board’s Audit Committee and Compensation Committee on the same date. The company granted him equity in lieu of cash director fees.

Key Details

• Appointment date: June 26, 2026; term: until next annual meeting or earlier resignation/removal.
• Committee assignments: Audit Committee and Compensation Committee (effective June 26, 2026).
• Equity compensation (in lieu of standard cash director pay):
  • Sign-on stock option for 90,000 shares, exercise price = fair market value on Grant Date (June 29, 2026), vesting quarterly over 36 months.
  • Replacement for annual cash retainer and committee fees: option for 446,428 shares, same exercise price and vesting (quarterly over 36 months).
• Background: health-care economist with roles in academia, government and industry (e.g., Acting Chairman of the White House Council of Economic Advisers June 2019–June 2020; Managing Partner of MEDA Ventures since 2023; founder of Precision Health Economics). Education includes a Ph.D. in Economics from Wharton.
• Filing notes there are no other arrangements or related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.

Why It Matters
The company added a director with extensive healthcare economics and policy experience and placed him on the Audit and Compensation Committees—areas important for financial oversight and executive pay. The use of equity (options vesting over three years) instead of cash reduces immediate cash outflow and aligns compensation with continued service and future stock performance. Investors should note the new committee composition and Dr. Philipson’s qualifications as facts from the filing when assessing board oversight and governance.